Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on May 15)
- Inspire Medical Systems Inc INSP
- Aptevo Therapeutics Inc APVO
- BioLife Solutions Inc BLFS
- Ligand Pharmaceuticals Inc. LGND
- MEI Pharma Inc MEIP
- OptiNose Inc OPTN
- ProPhase Labs Inc PRPH
- Regenxbio Inc RGNX
- Sophiris Bio Inc SPHS (reported Q1 results after Monday's close)
- Vericel Corp VCEL
- Xenon Pharmaceuticals Inc XENE (positive Phase 1 interim data for its epilepsy treatment XEN1101)
Down In The Dumps
(Stocks hitting 52-week lows on May 15)
- aTyr Pharma Inc LIFE
- BIOLASE Inc BIOL
- Cesca Therapeutics Inc KOOL (reported Q1 results after Monday's close)
- Immune Pharmaceuticals Inc IMNP (presented updated data from the Phase 2 study of its bertilimumab in patients with moderate-to-extensive bullous pemphigoid; filed an 8-K for selling up to $2.225 million of original discount convertible debentures)
Stocks In Focus
Verastem Announces $35 Million Stock Offering
Verastem Inc VSTM said it would offer $35 million worth of shares in a common stock offering. All shares offered are sold by the company.
The stock fell 11.07 percent to $4.66 in after-hours trading Tuesday.
Celyad Announces Global Offering
CELYAD SA/ADR CYAD announced its intention to offer up to 1.8 million ordinary shares in a global offering in the form of ADRs in the U.S., Canada and certain countries outside of Europe.
The stock slid 3.32 percent to $29.70 after hours.
See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates
Titan Posts Better-Than-Expected Q1
Titan Pharmaceuticals, Inc. TTNP reported Q1 revenues of $1.1 million, sharply higher than the $40,000 reported for the year-ago period. The company's net loss narrowed from 14 cents per share to 12 cents per share.
Analysts, on average, estimated a loss of 13 cents per share on revenues of $70,000.
The micro-cap stock jumped 25 percent after hours.
Zomedica Reports A Flat Loss For Q1
Zomedica Pharmaceuticals Corp ZOM announced a Q1 loss of 2 cents per share, flat with last year.
The stock rallied 6.25 percent to $2.04 after hours.
Biocept Q1 Misses Estimates
Biocept Inc BIOC said its Q1 loss per share narrowed from 21 cents to 11 cents, while revenues came in at $1.68 million. The year-ago revenues included a one-time revenue of $874,000 related to the conversion from cash-based to accrual-based revenue recognition.
The consensus estimates had called for a loss of 9 cents per share on revenues of $1.1 million.
The stock slumped 18.18 percent to $0.18 after hours.
Altimmune Q1 Loss Narrows, Revenues Surge
Altimmune Inc ALT reported a net loss of 25 cents per share, excluding non-cash goodwill impairment charges, compared to a loss of 68 cents in the year-ago period.
Revenues climbed from the year-ago's $0.3 million to $2.7 million.
The micro-cap stock gained 16.19 percent.
Other Stocks That Reacted to Earnings
(Tuesday's after-hours quote)
- Ritter Pharmaceuticals Inc RTTR – Up 1.38 percent to $2.94
- Imprimis Pharmaceuticals Inc IMMY – Up 5.44 percent to $2.52
- CorMedix Inc. CRMD – Down 2.35 percent to $0.1953
- Eleven Biotherapeutics Inc EBIO – Up 1.89 percent to $2.70
- Zosano Pharma Corp ZSAN – Up 2.97 percent to $4.86
On The Radar
The following companies report earnings on Wednesday:
- Bio-Path Holdings Inc BPTH
- Obseva SA OBSV
Other Events
Voyager Therapeutics Inc VYGR will release final Phase 1b data for its advanced Parkinson's disease treatment VY-AADC01 at the American Society of Gene & Cell Therapy, or ASGCT, 2018 Annual Meeting at 6 p.m. ET.
Audentes Therapeutics Inc BOLD is due to release final Phase 1/2 data for its X-linked Myotubular myopathy treatment AT132 at the ASGCT meeting at 11:30 a.m. ET.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.